Abstracts tagged "diabetes and rheumatoid arthritis (RA)"

Abstract Number: 538 • 2018 ACR/ARHP Annual Meeting
Type 1 Diabetes in RA: Comparison with Type 2 and Its Association with RA Severity and Treatment
Sofia Pedro¹, Gulsen Ozen² and Kaleb Michaud^1,2, ¹FORWARD, The National Databank for Rheumatic Diseases, Wichita, KS, ²Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: DMARD treatment for Rheumatoid Arthritis (RA) has been shown to improve the glucose control and reduce the incidence of diabetes, usually assumed to be…
Abstract Number: 871 • 2017 ACR/ARHP Annual Meeting
Coronary Microvascular Dysfunction in Rheumatoid Arthritis Compared to Diabetes Mellitus in Patients without Obstructive Coronary Artery Disease
Katherine P. Liao¹, Gabrielle Cremone², Ethan Lam², Zhi Yu¹, Jon M. Hainer³, Victoria Morgan³, Courtney Bibbo³ and Marcelo Di Carli³, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ²Rheumatology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³Nuclear Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Patients with DM have increased coronary microvascular dysfunction (CMD) compared to the general population, leading to higher rates of cardiac death despite normal perfusion…
Abstract Number: 2891 • 2017 ACR/ARHP Annual Meeting
Do Certain Dmards Increase Risk of New-Onset Type 2 Diabetes in RA Patients? a Disease Risk Score Analysis Using Administrative Databases
E Alemao, Z Guo and L Burns, Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: Data on the association between RA and type 2 diabetes mellitus (T2DM) are inconsistent, suggesting RA treatments such as glucocorticoids (GCs) and hydroxychloroquine could…
Abstract Number: 20 • 2016 ACR/ARHP Annual Meeting
Diabetes and Other Comorbidities in Rheumatoid Arthritis Patients Starting a Biologic DMARD: A Multi-Database Cohort Study
Seoyoung C. Kim^1,2, Yinzhu Jin³, Gregory Brill⁴, Jennifer Lewey^4,5, Nam-Kyong Choi³, Elisabetta Patorno⁴ and Rishi J. Desai³, ¹Rheumatology, Immunology and Allergy and Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, Boston, MA, ²Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, Boston, MA, ³Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, Boston, MA, ⁴Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital/Harvard Medical School, Boston, MA, ⁵Division of Cardiology, Columbia University Medical Center, New York, NY
Background/Purpose: Patients with rheumatoid arthritis (RA) are known to have an increased comorbidity burden. Presence of diabetes or other comorbidities such as cardiovascular disease (CVD)…
Abstract Number: 990 • 2016 ACR/ARHP Annual Meeting
Autoimmunity to Multiple Antigens Is Expanded in at-Risk Family Members Beyond the Disease Specific Patterns of the SLE or RA Proband
Judith A. James¹, Krista M. Bean², Hua Chen², Kendra A. Young³, Elizabeth A. Bemis⁴, Jennifer Seifert⁵, Maria Sargent⁶, Kevin D. Deane⁷, Bill Robinson⁸, David A. Hafler⁹, Kevin O'Conner¹⁰, Jane H. Buckner¹¹, Joel M. Guthridge¹², Jill M. Norris¹³ and V. Michael Holers¹⁴, ¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Epidemiology, University of Colorado Denver, Aurora, CO, ⁴Epidemiology, Colorado School of Public Health, Aurora, CO, ⁵University of Colorado, Denver, CO, ⁶Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁷Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ⁸Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ⁹Neurology and Immunobiology, Yale School of Medicine, New Haven, CT, ¹⁰Yale University, New Haven, CT, ¹¹Benaroya Research Institute at Virginia Mason, Seattle, WA, ¹²Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹³University of Colorado Denver, Aurora, CO, ¹⁴Rheumatology Division, University of Colorado School of Medicine, Aurora, CO
Background/Purpose: Certain autoantibodies (aabs) are highly disease specific, can be detected prior to the onset of clinically apparent disease and oftentimes increase in number and…
Abstract Number: 2609 • 2015 ACR/ARHP Annual Meeting
The Measurement of the Skin Autofluorescence As an Indicator of Disease Progression in Rheumatoid Arthritis Patients
Slawomir Jeka¹, Pawel Zuchowski², Katarzyna Kolossa³, Marta Dura⁴ and Rafal Wojciechowski⁵, ¹Clinic of Rheumatology and Connective Tissue Diseases, University Hospital Nr 2 Dr. Jan Biziel, 85-168 Bydgoszcz, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Poland, Bygdoszcz, Poland, ²Independent Section of Scientific Research Coordination and Didactic Activity, University Hospital Nr 2 Dr. Jan Biziel, 85- 168 Bydgoszcz, Poland, Bygdoszcz, Poland, ³Clinic of Rheumatology and Connective Tissue Diseases, University Hospital Nr 2 Dr. Jan Biziel, 85- 168 Bydgoszcz, Poland, Bygdoszcz, Poland, ⁴Department of Radiology and Medical Imaging, University Hospital Nr 2 Dr. Jan Biziel, 85- 168 Bydgoszcz, Poland, Bygdoszcz, Poland, ⁵Clinic of Rheumatology and Connective Tissue Diseases, University Hospital Nr 2 Dr. Jan Biziel, 85-168 Bydgoszcz, Poland, Bydgoszcz, Poland
Background/Purpose: In course of rheumatoid arthritis (RA) ther is often impaired glucose metabolism, which leads to the development of diabetes mellitus (DM). One of the…
Abstract Number: 1040 • 2013 ACR/ARHP Annual Meeting
Use Of TNF Inhibitors Is Associated With a Reduced Risk Of Diabetes In RA Patients
Siri Lillegraven¹, Jeffrey D. Greenberg², George W. Reed³, Katherine C. Saunders³, Jeffrey R. Curtis⁴, Leslie R. Harrold⁵, Marc C. Hochberg⁶, Dimitrios A. Pappas⁷, Joel M. Kremer⁸ and Daniel H. Solomon⁹, ¹Diakonhjemmet Hospital, Oslo, Norway, ²NYU Hospital for Joint Diseases, New York, NY, ³Corrona, LLC., Southborough, MA, ⁴Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵University of Massachusetts Medical School, Worcester, MA, ⁶Medicine, University of Maryland School of Medicine, Baltimore, MD, ⁷Department of Medicine, Division of Rheumatology, Columbia University, College of Physicians and Surgeons, New York, NY, ⁸Center for Rheumatology, Albany Medical College, Albany, NY, ⁹Division of Pharmacoepidemiology, Harvard Medical School, Brigham and Women's Hospital, Division of Rheumatology, Division of Pharmacoepidemiology, Boston, MA
Background/Purpose: Inflammation may contribute to diabetes risk, and some studies indicate that certain DMARDs might be associated with a reduced risk of diabetes. Most studies…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].